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Abstract
Background and objectives Colesevelam significantly
lowers cholesterol in patients with hypercholesterolemia,
and both cholesterol and hemoglobin A1C (A1C) in
patients with type 2 diabetes mellitus (T2DM). The pur-
pose of this post hoc analysis was to evaluate the efficacy
and safety/tolerability of colesevelam in older (C65 years)
and younger (\65 years) adults.
Methods We conducted post hoc analyses of pooled clin-
ical trial data from seven phase II and III randomized, dou-
ble-blind, placebo-controlled, primary hyperlipidemia and
T2DM clinical trials. The hyperlipidemia safety/tolerability
analysis included seven studies (C65 years, n = 154;
\65 years, n = 381); the efficacy analysis utilized one
study with sufficient patients in both age groups for mean-
ingful comparison. The T2DM analyses included four
studies (safety/tolerability: C65 years, n = 249;\65 years,
n = 880) or three studies (efficacy). In the hyperlipidemia
studies, patients received colesevelam 1.5–4.5 g/day or
placebo, alone or with a statin, for 4 weeks to 6 months. In
the T2DM studies, colesevelam 3.75 g/day or placebo was
added to existing antidiabetes therapies for 16 or 26 weeks.
Low-density lipoprotein cholesterol (LDL-C), A1C, and
adverse events were assessed.
Results In the hyperlipidemia analysis, colesevelam ver-
sus placebo produced similar mean reductions from base-
line in LDL-C in older (-16.6 vs. ?0.5 %) and younger
(-13.7 vs. ?0.4 %) patients. In the T2DM analysis, older
and younger patients had similar reductions from baseline
in A1C (treatment difference -0.59 and -0.54 %, respec-
tively; both p \ 0.001) and LDL-C (-14.7 and -15.5 %,
respectively; both p \ 0.001) with colesevelam. In both
analyses, adverse event incidence was generally similar
between subgroups. In the T2DM analysis, hypoglycemia
was slightly more frequent with colesevelam versus placebo
in older patients (5.8 vs. 2.3 %); no reports of hypoglycemia
were considered serious adverse events.
Conclusions In primary hyperlipidemia and in T2DM,
colesevelam appeared to be generally as safe, well toler-
ated, and efficacious in patients aged C65 years as in those
aged \65 years.
1 Background and Objectives
The population in the USA aged C65 years has a dispro-
portionately high prevalence of dyslipidemia (65–74 years,
37.1 %; 75–84 years, 37.7 %) [1] and diabetes mellitus
(26.9 %) [2], both of which are risk factors for cardio-
vascular disease [3]. Achieving recommended treatment
targets for hypercholesterolemia and diabetes can be dif-
ficult with lifestyle modification alone, and typically
requires pharmacological therapy [4–6]. It is important to
note that although clinical practice guidelines have his-
torically focused on achieving specific low-density lipo-
protein cholesterol (LDL-C) targets to reduce
cardiovascular disease risk, the recently published
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American College of Cardiology/American Heart Associ-
ation guidelines have instead placed the emphasis on
reducing risk in patient groups known to be at a high risk for
cardiovascular disease, and using the appropriate intensity
of statin therapy to reduce risk. The optimal LDL-C goal
has remained the same; however, the clinical focus has
shifted to who can most benefit from statin therapy as well
as using higher-dose statins instead of a low-dose statin
combined with a cholesterol-lowering agent from another
drug class. These guidelines represent a change in the his-
torical treatment paradigm that is still being debated and is
discussed in more detail below [7].
Standard and intensive doses of statins are effective in
reducing LDL-C levels [8]. However, for patients who are
unable to tolerate maximal doses of statins, or who do not
achieve treatment targets with such therapy, combination
therapy with statins may be necessary. The Lipid Treat-
ment Assessment Project found that National Cholesterol
Education Program LDL-C targets were achieved by 40 %
of patients receiving statin monotherapy overall and 18 %
of those with coronary heart disease (CHD) [5]. Add-on
therapies can enhance the cardiovascular benefits; each
mmol/L (39 mg/dL) reduction in LDL-C has been shown
to be associated with a 19 % reduction in coronary mor-
tality and a 21 % reduction in risk of any major vascular
event (p \ 0.001 for both) [9].
Similarly, an analysis of National Health and Nutrition
Examination Survey data (excluding patients likely to have
type 1 diabetes) showed that in 2003–2006, hemoglobin
A1C (A1C) \7.0 % was achieved by 57 % of patients
overall (64 % of those aged C60 years) [10]. There is a
progressive requirement for multiple therapies to achieve
glycemic control in patients with type 2 diabetes mellitus
(T2DM) [11]. Nevertheless, each 1 % reduction in A1C
has been shown to be associated with a 21 % reduction in
risk for deaths related to diabetes and a 14 % reduction in
risk for myocardial infarction (p \ 0.001 for both) [12].
Drug safety is an important consideration in the treat-
ment of elderly patients. Indeed, this is among the leading
considerations driving the current consensus around the
requirement for individualization of treatment for older
patients with T2DM who have a longer duration of disease
or more complicated disease [13]. Furthermore, in the USA,
the expanding population aged C65 years is included in the
Medicare population, and it is important in the current cli-
mate to show that drugs are safe and efficacious in this
population. Although numerous pharmacological options
are available for lipid and glycemic control, special care
must be taken in prescribing for elderly patients, who may
be more susceptible to adverse effects due to age-related
changes in pharmacokinetics and pharmacodynamics [14,
15]. The risk of muscle-related adverse effects associated
with 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors
(statins), which are considered first-line lipid-lowering
therapy, appears to increase with increasing age [16].
In a study examining hospitalizations for adverse drug
events among the elderly population in the USA, two-thirds
of hospitalizations were attributable to four drugs or drug
classes (alone or in combination); two of these drugs/drug
classes were diabetes treatments (insulins 13.9 %; oral
antidiabetes drugs 10.7 %) [17]. Drug-induced hypogly-
cemia is an important consideration for antidiabetes ther-
apies, particularly sulfonylureas [14]. Elderly patients with
T2DM are at increased risk of hypoglycemia compared
with younger patients [18], leading to increased risk for
falls [19] and fall-related fractures [20]. In addition, elderly
patients with T2DM display unawareness of hypoglycemia
relative to middle-aged patients, which may contribute to
an increased risk of developing severe hypoglycemia [21].
Thiazolidinediones are associated with adverse effects that
may limit their use in elderly patients [15]; these include
edema and potential congestive heart failure, and fractures
[14, 22–24].
Colesevelam hydrochloride is a bile acid sequestrant
that was designed to have a high affinity and capacity to
bind bile acids. It is unabsorbed by the body and its dis-
tribution is confined to the digestive tract. Colesevelam
binds to bile acids in the intestine, and these complexes are
excreted in the feces [25], thereby decreasing the bile acid
pool. Correspondingly, there is an increased conversion of
cholesterol to bile acids that results in a compensatory
uptake of LDL-C by the liver from the blood, which ulti-
mately decreases serum LDL-C. The glucose-lowering
mechanism of colesevelam is not completely understood;
however, it is believed that its binding to bile acids acti-
vates a G-protein-coupled receptor for bile acids that
results in increased secretion of GLP-1, and perhaps other
incretins, which inhibits hepatic glycogenolysis [26–28].
Colesevelam is approved by the US FDA as an adjunct to
diet and exercise for the reduction of LDL-C in adults with
primary hyperlipidemia (Fredrickson Type IIa) or in boys
and postmenarchal girls (aged 10–17 years) with hetero-
zygous familial hypercholesterolemia, as monotherapy or
in combination with a statin, and also for improvement of
glycemic control in adults with T2DM in combination with
oral antidiabetes drugs and insulin [29]. In double-blind
placebo-controlled trials in patients with moderate hyper-
cholesterolemia, colesevelam was shown to be effective in
lowering LDL-C levels (13–21 % reduction vs. placebo)
and was generally well tolerated [25, 30, 31], with less
constipating effect than other bile acid sequestrants [30]. In
adults with T2DM inadequately controlled by sulfonylurea-,
metformin-, or insulin-based therapy, the addition of
colesevelam significantly reduced A1C (-0.5 % reduction
vs. placebo) and LDL-C levels (13–17 % reduction vs.
placebo) and was generally well tolerated in three double-
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blind, placebo-controlled, parallel-group, multicenter
studies [32–34].
Although the safety and efficacy of colesevelam have
been well documented in the general population, its safety
and efficacy have been less extensively evaluated in older
patients. Here, we report the results of post hoc integrated
analyses of pooled clinical trial data conducted to evaluate
the efficacy and safety/tolerability of colesevelam in older
adults (men and women aged C65 years) as well as
younger adults aged \65 years.
2 Methods
2.1 Primary Hyperlipidemia Analysis
This was a post hoc analysis of the pooled data from
patients with hyperlipidemia (N = 1,350) included in
seven phase II and III randomized, double-blind, placebo-
controlled clinical studies designed to establish the safety
and efficacy of colesevelam as a monotherapy or in com-
bination with a statin (lovastatin, simvastatin, or atorva-
statin). The studies enrolled patients aged C18 years with
primary hypercholesterolemia. Patients received coleseve-
lam 1.5–4.5 g/day or placebo for durations ranging from
4 weeks to 6 months. The demographic characteristics of
the treatment categories (placebo, colesevelam only,
colesevelam/statin, statin only) and colesevelam dose
groups (placebo, low, medium, high) created from the
integrated database were very similar, with the single
exception of duration of exposure. Due to a low number of
older patients in the hyperlipidemia studies, no formal
statistical analysis had been performed in these studies.
2.1.1 Efficacy
A pivotal 6-month phase III dose-ranging study that dem-
onstrated the long-term safety and efficacy of colesevelam
monotherapy in a larger patient population was sufficiently
large enough for analysis of drug–demographic efficacy
interactions. This study included 133 patients aged
\65 years (colesevelam, n = 68; placebo, n = 65) and 50
patients aged C65 years (colesevelam, n = 27; placebo,
n = 23). Efficacy parameters included mean percent
changes from baseline to study end in LDL-C and tri-
glyceride levels.
2.1.2 Safety
The safety and tolerability analysis included data from all
seven studies. These studies included 381 patients aged
\65 years (colesevelam, n = 289; placebo, n = 92) and
154 patients aged C65 years (colesevelam, n = 117;
placebo, n = 37). Safety and tolerability were evaluated on
the basis of adverse events (AEs).
2.2 Integrated Type 2 Diabetes Mellitus (T2DM)
Analysis
2.2.1 Efficacy
This was a post hoc analysis of the pooled data from all
patients (N = 1,018) included in three double-blind, pla-
cebo-controlled, pivotal trials of colesevelam as add-on
therapy for patients with T2DM inadequately controlled
with metformin-, insulin-, or sulfonylurea-based therapy
[32–34]. The studies enrolled patients aged 18–75 years
with T2DM who had A1C values of 7.5–9.5 %. In all three
trials, colesevelam (3.75 g/day) or placebo was added on to
patients’ established antidiabetes therapies for 16 weeks
(insulin-based therapy study) or 26 weeks (metformin- and
sulfonylurea-based therapy studies). The studies included a
total of 790 patients aged \65 years (colesevelam,
n = 402; placebo, n = 388) and 228 patients aged
C65 years (colesevelam, n = 110; placebo, n = 118).
Efficacy parameters included mean change in A1C and
fasting plasma glucose (FPG), and mean percent changes
in LDL-C, total cholesterol (TC), high-density lipopro-
tein cholesterol (HDL-C), non-HDL-C, triglyceride,
apolipoprotein (apo) A-I, and apo B, from baseline to
study end.
2.2.2 Safety
The safety analysis included pooled data from the same
three pivotal trials [32–34], plus those from a small ran-
domized, double-blind, placebo-controlled pilot study that
included patients inadequately controlled on metformin
and/or sulfonylureas [35]. Thus, this safety/tolerability
pooled analysis included a total of 249 patients aged
C65 years (colesevelam, n = 121; placebo, n = 128) and
880 patients aged \65 years (colesevelam, n = 446; pla-
cebo, n = 434). One subject aged \65 years was ran-
domized to colesevelam but did not take the study
medication and therefore was not included in the safety
analysis. Safety and tolerability were evaluated on the basis
of AEs.
2.3 Ethical Standards
All clinical studies were conducted in accordance with the
ethical principles outlined in the Declaration of Helsinki.
The protocol and informed consent documents at each site
were approved by an Institutional Review Board. All
subjects provided informed consent prior to entering any of
the studies.
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3 Results
3.1 Integrated Primary Hyperlipidemia Analysis
3.1.1 Efficacy
Colesevelam monotherapy resulted in similar mean
reductions from baseline in LDL-C levels compared with
placebo in both patients aged C65 years (-16.6 %
[n = 27] vs. ?0.5 % [n = 23]) and those aged \65 years
(-13.7 % [n = 68] vs. ?0.4 % [n = 65]). These changes
in LDL-C were accompanied by a similar modest increase
from baseline in levels of triglyceride with colesevelam
compared with placebo in both patients aged C65 years
(?13.4 % [n = 27] vs. ?2.9 % [n = 23]) and those aged
\65 years (?12.7 % [n = 68] vs. ?3.1 % [n = 65]).
3.1.2 Safety
Colesevelam therapy was generally well tolerated in the
primary hyperlipidemia studies. The most common AEs
were gastrointestinal, including constipation and dyspepsia
(Table 1); the incidence of these AEs was similar in both
age subgroups.
3.2 Integrated T2DM Analysis
3.2.1 Efficacy
In patients aged C65 years as well as those aged
\65 years, colesevelam treatment added to existing thera-
pies resulted in similar reductions from baseline in A1C
(Fig. 1a) and FPG (Fig. 1b). Adding colesevelam to
existing therapies also resulted in similar reductions from
baseline in LDL-C and non-HDL-C and similar increases
in triglycerides in both age subgroups (Fig. 2). Both older
and younger patients also had similar reductions from
baseline in apo B (data not shown) and increases in apo A-I
(data not shown) with colesevelam, while no significant
changes in HDL-C levels (Fig. 2) were seen with coles-
evelam treatment in either age subgroup.
3.2.2 Safety
Overall, treatment with colesevelam was safe and generally
well tolerated. The overall incidence of AEs was slightly
higher with colesevelam than with placebo in both age
subgroups, with slightly lower values overall in patients
aged \65 years (Table 2). Serious AE incidence rates in
patients aged C65 years were lower with colesevelam
than with placebo and similar to those in patients aged
\65 years. Maximum treatment-emergent AE severity was
mild-to-moderate in the majority of patients in both treat-
ment groups among both age groups. The rate of with-
drawals due to AEs was relatively low overall, but slightly
higher with colesevelam, compared with placebo, among
both patients aged C65 years (8.3 vs. 6.3 %) and those aged
\65 years (6.3 vs. 2.3 %), and again slightly lower in the
younger subgroup.
In both age subgroups, the incidence of constipation was
higher with colesevelam than with placebo (Table 2).
However, the imbalance between treatment groups was less
pronounced in patients aged C65 years, despite the higher
overall incidence of constipation in this subgroup. In both
age subgroups, the incidence of diarrhea was lower with
colesevelam than with placebo. Dyspepsia was less fre-
quent in patients aged C65 years and similar between
treatments. Although hypoglycemia was slightly more
frequent with colesevelam than with placebo among
patients aged C65 years, but not those aged \65 years, no
episode of hypoglycemia was considered a serious AE.
It should be noted that the study was not powered to
detect statistically significant differences in the incidence
of specific AEs between the age cohorts and, therefore, no
statistical analysis was performed.
Table 1 Adverse events in
patients aged \65 years and
C65 years in the integrated
primary hyperlipidemia analysis
occurring in C2 % of patients













Constipation 63 (10.3) 15 (7.9) 26 (13.4) 3 (4.4)
Dyspepsia 54 (8.8) 8 (4.2) 13 (6.7) 1 (1.5)
Nausea 29 (4.7) 8 (4.2) 5 (2.6) 2 (2.9)
Accidental injury 21 (3.4) 6 (3.2) 9 (4.6) 1 (1.5)
Asthenia 25 (4.1) 5 (2.6) 4 (2.1) 0 (0.0)
Pharyngitis 22 (3.6) 4 (2.1) 2 (1.0) 0 (0.0)
Flu syndrome 21 (3.4) 6 (3.2) 4 (2.1) 2 (2.9)
Rhinitis 19 (3.1) 7 (3.7) 7 (3.6) 1 (1.5)
Myalgia 16 (2.6) 1 (0.5) 1 (0.5) 0 (0.0)
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4 Discussion
In these integrated analyses, the safety and tolerability
profile of colesevelam was generally similar in older
patients compared with younger patients. Certain gastro-
intestinal AEs were slightly more common with
colesevelam than with placebo; however, AEs were gen-
erally mild-to-moderate and did not often result in drug
discontinuation. In addition, colesevelam was effective in
lowering LDL-C in patients with primary hyperlipidemia
aged C65 years; these beneficial effects were similar to
those observed in patients aged \65 years. Furthermore,
Fig. 1 Mean changes from baseline in a A1C (measured in percentage units) and b FPG in the integrated type 2 diabetes mellitus analysis, by
age subgroup. A1C hemoglobin A1C, FPG fasting plasma glucose
Fig. 2 Mean changes from
baseline in LDL-C, non-HDL-
C, and HDL-C and median
change from baseline in TG in
the integrated type 2 diabetes
mellitus analysis, by age
subgroup. Asterisk indicates that
the parameter is not normally
distributed so median values are
reported. The interquartile range
values for patients aged
\65 years and C65 years were
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colesevelam was an efficacious add-on treatment for
improving both glycemic control and lipid management in
adults with T2DM on various antidiabetes regimens; the
effects of colesevelam on diabetic and lipid parameters
were consistent in patients aged \65 and C65 years when
added to existing antidiabetes therapies. The results from
the integrated T2DM study analysis showed that coles-
evelam had a minimal impact on HDL-C levels, i.e.,
patients aged \65 years had an insignificant decrease
whereas those C65 years had an insignificant increase in
HDL-C levels. This is consistent with existing data show-
ing that colesevelam typically has a neutral effect on, or
may slightly increase, HDL-C levels [29, 36].
The selection of pharmacological therapies for older
patients requires special care and consideration [15]. In
particular, older patients may be more susceptible to
adverse effects [14], potentially limiting the ability to use
certain drugs, or use of higher doses. For example, the
incidence of myotoxicity associated with statin therapy
appears to increase with increasing age [16], and is also
higher with intensive-dose statin therapy [37]. The preva-
lence of diabetes increases with age, and therefore the use
of drugs with potential diabetogenic effects in the elderly
population is of concern. Niacin has been associated with
modest adverse effects on glycemic control [38], and statin
therapy (particularly intensive-dose) has been associated
with concerns regarding increased risk of developing dia-
betes [39–41]. It has been suggested that the cardiovascular
benefits of statins outweigh any negative glycemic effects
[42]; however, it may be prudent to avoid any potential
Table 2 Adverse events in patients aged \65 years and C65 years in the integrated type 2 diabetes mellitus analysis occurring in C2 % of
patients
AE, n (%) \65 years C65 years
Colesevelam (n = 445) Placebo (n = 434) Colesevelam (n = 121) Placebo (n = 128)
All TEAEs 261 (58.7) 236 (54.4) 81 (66.9) 76 (59.4)
Abdominal pain 8 (1.8) 3 (0.7) 3 (2.5) 1 (0.8)
Arthralgia 6 (1.3) 8 (1.8) 4 (3.3) 8 (6.3)
Back pain 9 (2.0) 8 (1.8) 2 (1.7) 2 (1.6)
Bronchitis 9 (2.0) 10 (2.3) 1 (0.8) 5 (3.9)
Chest pain 4 (0.9) 4 (0.9) 3 (2.5) 0 (0.0)
Constipation 35 (7.9) 5 (1.2) 14 (11.6) 6 (4.7)
Cough 5 (1.1) 11 (2.5) 3 (2.5) 2 (1.6)
Diarrhea 9 (2.0) 12 (2.8) 2 (1.7) 4 (3.1)
Dizziness 5 (1.1) 4 (0.9) 3 (2.5) 1 (0.8)
Dyspepsia 19 (4.3) 6 (1.4) 3 (2.5) 2 (1.6)
Headache 8 (1.8) 16 (3.7) 1 (0.8) 3 (2.3)
Hypoglycemia 10 (2.2) 10 (2.3) 7 (5.8) 3 (2.3)
Hypertension 10 (2.2) 8 (1.8) 6 (5.0) 1 (0.8)
Influenza 9 (2.0) 13 (3.0) 2 (1.7) 0 (0.0)
Muscle strain 1 (0.2) 1 (0.2) 3 (2.5) 1 (0.8)
Nasopharyngitis 21 (4.7) 17 (3.9) 2 (1.7) 3 (2.3)
Nausea 14 (3.1) 7 (1.6) 3 (2.5) 1 (0.8)
Pain in extremity 7 (1.6) 4 (0.9) 2 (1.7) 3 (2.3)
Palpitations 1 (0.2) 0 (0.0) 3 (2.5) 0 (0.0)
Peripheral edema 4 (0.9) 7 (1.6) 3 (2.5) 2 (1.6)
Pneumonia 3 (0.7) 1 (0.2) 1 (0.8) 3 (2.3)
Sinusitis 10 (2.2) 12 (2.8) 1 (0.8) 1 (0.8)
Upper respiratory tract infection 24 (5.4) 30 (6.9) 6 (5.0) 5 (3.9)
Urinary tract infection 14 (3.1) 17 (3.9) 7 (5.8) 5 (3.9)
Vomiting 10 (2.2) 3 (0.7) 2 (1.7) 0 (0.0)
Drug-related TEAEs 82 (18.4) 37 (8.5) 27 (22.3) 15 (11.7)
Serious AEs 22 (4.9) 16 (3.7) 5 (4.1) 10 (7.8)
Drug-related serious AEs 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
AE adverse event, TEAE treatment-emergent AE
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increased risk of diabetes in the elderly population. This
constitutes yet another consideration for combination or
alternative therapies. Colesevelam achieves additive LDL-C
reductions of approximately 16 % when used in combination
with statins [43].
Constipation is common in the elderly population [44];
therefore, the incidence of constipation as an AE may be of
particular relevance when treating elderly patients. In the
current analyses, while the incidence of constipation was
higher with colesevelam than with placebo, as has previ-
ously been observed, it was notable that the imbalance
between the colesevelam and placebo groups was less
pronounced among the older patients, despite the overall
incidence of constipation being higher in the older group.
Interestingly, in the integrated T2DM analysis, the inci-
dence of diarrhea was lower with colesevelam than with
placebo among both age groups. This finding may have
been influenced by patients who had study medication
added to a regimen that included metformin, which is well
known to be associated with the development of diarrhea
[45]. The gastrointestinal effects of metformin, together
with weight loss effects, may even be detrimental to frail
elderly patients [14]. Hypothetically, the slightly consti-
pating effects of colesevelam may have somewhat coun-
teracted the diarrhea-inducing effects of metformin,
reducing the incidence of diarrhea in the colesevelam
group. A similar reduction in diarrhea was seen with
colesevelam versus placebo as add-on therapy to metfor-
min in patients with early T2DM in a previous study [46].
Although tight glycemic control is beneficial in reducing
the risk of diabetic complications in patients with T2DM,
as shown in the UK Prospective Diabetes Study [12],
avoidance of hypoglycemia is especially important, par-
ticularly for elderly patients who may be at increased risk
of hypoglycemia [18], which can lead to falls and fall-
related fractures [19, 20]. Compared with other oral an-
tidiabetes agents, sulfonylureas and repaglinide are asso-
ciated with a greater risk of hypoglycemia in adults with
T2DM [47]. A consensus panel convened by the American
Diabetes Association recommends that glyburide, which
has the highest risk of hypoglycemia among the sulfonyl-
ureas, should not be prescribed to older patients [14]. In the
current integrated T2DM analysis, the incidence of hypo-
glycemia was similar with colesevelam and placebo among
patients aged\65 years, and was only slightly higher with
colesevelam among patients aged C65 years. This increase
in hypoglycemia in the older subgroup may have reflected
the higher propensity for hypoglycemia in older patients
[18]. Nevertheless, the rates of hypoglycemia remained
considerably lower than those reported with other classes
of drugs, such as sulfonylureas (up to 36 %) [47].
Age-specific hypoglycemic data were not analyzed for
each of the antidiabetic agent T2DM studies individually;
however, the following data are reported in the literature
for the colesevelam and placebo total population cohorts to
provide a relative assessment of the incidence of hypo-
glycemia associated with the individual antidiabetic agents
in combination with colesevelam. No significant changes in
the incidence of hypoglycemia were noted in the small
T2DM pilot study wherein colesevelam was added to sul-
fonylurea and/or metformin [35]. Colesevelam as add-on
therapy to metformin-based therapy [32] reported one
patient in the colesevelam group experienced mild hypo-
glycemia. Colesevelam as add-on therapy to insulin-based
therapy [34] had a reported incidence of hypoglycemia in
the colesevelam versus placebo group of 3.4 and 5.7 %,
respectively, and colesevelam as add-on therapy to sulfo-
nylurea-based therapy [33] reported six patients experi-
enced hypoglycemia versus two patients in the placebo
group. No patient discontinued from any of the studies due
to hypoglycemia.
One should keep in mind that both renal and hepatic
functions diminish with advancing age, requiring consid-
eration in the selection of pharmacological agents in
elderly patients [48]. For example, pharmacokinetic studies
of metformin in healthy elderly subjects indicate that
plasma clearance is decreased, half-life is prolonged, and
peak plasma concentration is increased, due primarily to
likely changes in renal function associated with aging [49].
Another important consideration is the frequent use of
polypharmacy among elderly adults and the possibility of
drug interactions and altered pharmacokinetics that may
result [50]. Because bile acid sequestrants are not absorbed,
they do not cause many of the systemic toxicities that may
occur with other classes of lipid-lowering drugs [51]. In
addition, colesevelam has been shown to have a low pro-
pensity for drug–drug interactions [29, 52–55]. Where an
interaction is apparent with a concomitant medication, the
effect can typically be avoided by administration of
colesevelam 4 h after the other drug [29].
Our analyses showed a modest increase in triglyceride
levels with colesevelam, the clinical significance of which
remains unclear. Elevated triglyceride levels seem to be a
synergistic risk factor for CHD rather than an independent
risk factor [56]. In the Lipid Research Clinics Program
trial, the risk for CHD was decreased with the reduction of
LDL-C even when there was a concurrent modest elevation
in triglycerides [57, 58]. However, a prospective cohort
study of an elderly outpatient population showed that a
triglyceride level[200 mg/dL was a significant risk factor
for cardiovascular events, irrespective of the presence of
hypertension, abdominal obesity, or diabetes [59]. Con-
founding the issue even further, the CASTEL (CArdio-
vascular STudy in the ELderly) study by Mazza et al. [60]
showed that a high triglyceride level was an independent
predictor of CHD mortality in elderly women but did not
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have a predictive role in men. Consequently, additional
studies will be needed before a definitive statement can be
made regarding the role of triglycerides as a coronary risk
factor in older patients [60]. Presently, we believe the
modest triglyceride increase of 15 % in the present study
should be interpreted in conjunction with the benefit of
colesevelam therapy in reducing LDL-C, non-HDL-C, and
apo B levels [61].
The 2013 American College of Cardiology/American
Heart Association guidelines [7] were published recently;
although it was beyond the scope of this study to review
these guidelines, it is noteworthy that they focus on
reducing atherosclerotic cardiovascular disease risk
(ASCVD) and recommend high- and moderate-intensity
statin therapy for use in secondary and primary prevention.
These guidelines also recommend using the appropriate
intensity of statin therapy to reduce ASCVD risk in patients
most likely to benefit from such treatment. The guidelines
use the intensity of statin therapy as the goal of treatment
instead of LDL-C or non-HDL-C targets. As such, non-
statin cholesterol-lowering agents can be added if the
maximum tolerated intensity of statin treatment results in a
less-than-anticipated therapeutic response in patients at
higher ASCVD risk. However, it is currently unclear as to
how these new guidelines will affect the historical use of
non-statin lipid-lowering agents used either as mono-
therapy or in combination with a statin.
A potential limitation of this study is that the number of
older patients evaluated in the hyperlipidemia analyses was
relatively small; however, it should be noted that it had a
sufficient number of patients to perform statistical analyses.
A limitation of the study is that the age range of patients
making up the older patient cohort in the integrated T2DM
analyses was 65–75 years; consequently, it is not known
whether the safety and efficacy findings would also be
applicable to patients aged [75 years. Therefore, caution
should be used in extrapolating the data to age groups
beyond those evaluated. In addition, the primary hyper-
lipidemia analysis only included patients who had primary
hypercholesterolemia, and the integrated T2DM analysis
only included patients with T2DM; thus, the findings from
these individual analyses cannot be extrapolated to patients
having other types of lipid disorders, metabolic disorders,
or both hyperlipidemia and T2DM. Another limitation is
that although there are data showing that a bile acid se-
questrant can reduce the risk of cardiovascular events [58],
there have not been any randomized clinical trials assessing
the effect of colesevelam in improving cardiovascular
outcomes/reducing cardiovascular events. Thus, it is cur-
rently unknown whether the significant improvement in
both the lipid profile and the glycemic control observed
with colesevelam administration translates into a reduction
in cardiovascular risk in either cohort evaluated. Finally,
the data reported in this study were obtained from post hoc
analyses of previously conducted pooled analyses rather
than performing a meta-analysis of the evaluated coles-
evelam studies, which would have been more robust sta-
tistically. As such, some statistical analyses could not be
performed.
5 Conclusions
Among both patients with primary hyperlipidemia and
patients with T2DM, colesevelam appeared to be generally
as safe and well tolerated in patients aged C65 years as in
those aged \65 years. In patients aged C65 years, coles-
evelam had similar efficacy to that seen in patients aged
\65 years both for lowering LDL-C levels among patients
with primary hypercholesterolemia and for lowering A1C
and LDL-C levels among patients with T2DM.
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